Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/45724COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Título: | In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma |
Autor: | Ocio, Enrique M. CSIC ORCID ; Vilanova, David; Maiso, Patricia; Crusoe, Edvan; Fernández-Lázaro, Diego CSIC ORCID; Garayoa, Mercedes CSIC ORCID ; San-Segundo, Laura CSIC; Hernández, Mª Teresa; San Miguel, Jesús F. CSIC ORCID | Palabras clave: | Panobinostat LBH589 Multiple myeloma HDAC Inhibitors |
Fecha de publicación: | 1-may-2010 | Editor: | Ferrata Storti Foundation | Citación: | Haematologica 95(5): 794-803 (2010) | Resumen: | [Background]: Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed disease. We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile. [Design and Methods]: The activity of these combinations was explored in vitro in cell lines by using MTT and annex-in V, ex vivo by flow cytometry, and in vivo using two different murine models of human myeloma: one bearing a subcutaneous plasmacytoma and another with a disseminated myeloma. Moreover, gene expression profiling and immunohistochemical studies were performed. [Results]: The addition of panobinostat (LBH589) to dexamethasone and either bortezomib or lenalidomide resulted in clear potentiation in multiple myeloma cell lines, freshly isolated plasma cells, and murine models of multiple myeloma. The quantification of the potency of these combinations by using the Chou-Talalay method showed synergistic combination indices for all of them. This effect derived from the deregulation of a cluster of genes that was completely different from the sum of genes affected by the single agents (895 and 1323 genes exclusively deregulated by panobinostat and dexamethasone plus bortezomib or lenalidomide, respectively). Functional experiments, such as annexin V staining, cell cycle analysis, and immunohistochemical studies also supported this potentiation. Anti-myeloma efficacy was confirmed in an extramedullary plasmacytoma model and a disseminated luciferized model, in which panobinostat also provided a marked benefit in bone disease. [Conclusions]: The potent activity, together with the exclusive mechanistic profile, provides the rationale for the clinical evaluation of these drug combinations in multiple myeloma. | Descripción: | 10 páginas, 5 figuras.-- et al. | Versión del editor: | http://dx.doi.org/10.3324/haematol.2009.015495 | URI: | http://hdl.handle.net/10261/45724 | DOI: | 10.3324/haematol.2009.015495 | ISSN: | 0390-6078 |
| Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| 10.3324-haematol.2009.015495.pdf | 3,87 MB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
56
checked on 07-abr-2024
SCOPUSTM
Citations
136
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
134
checked on 29-feb-2024
Page view(s)
470
checked on 22-abr-2024
Download(s)
311
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.